论著

腕踝针联合揿针治疗带状疱疹后遗痛的临床疗效观察

Clinical efficacy of wrist and ankle acupuncture combined with thumbtack needle in the treatment of postherpetic herpes zoster pain

:650-655
 
       目的   探究腕踝针联合揿针治疗带状疱疹后遗痛的临床疗效观察。方法   选取上海市黄浦区中西医结合医院2021年10月—2024年4月收治的80例带状疱疹后遗神经痛患者为研究对象,按随机数表法分为研究组、对照组,各40例。对照组采用口服甲钴胺治疗;研究组采用腕踝针联合揿针治疗。比较两组治疗疗效;治疗前后采用视觉模拟评分(VAS)与阿森斯失眠量表评分(AIS)、皮肤病生活质量指数(DLQI)、汉密尔顿抑郁量表评分(HAMD)、汉密尔顿焦虑量表评分(HAMA)。结果   研究组治疗总有效率为92.5%,对照组治疗总有效率为75%。比较差异有统计学意义(P<0.05)。两组患者治疗后VAS、AIS均比治疗前改善,研究组VAS评分为(1.00±0.45)、AIS评分为(7.15±0.89),优于对照组VAS(2.15±0.36)和AIS(5.65±0.70),比较差异有统计学意义(P<0.05)。相较于治疗前,两组患者DLQI评分均有改善,研究组[休闲活动评分(1.73±0.45)、人际交往评分(1.13±0.34)、工作学习评分(0.94±0.25)、自觉症状评分(1.83±0.38)、日常活动评分(0.98±0.28)]优于对照组[休闲活动评分(2.06±0.40)、人际交往评分(1.81±0.39)、工作学习评分(1.08±0.38)、自觉症状评分(2.01±0.34)、日常活动评分(1.10±0.30)],差异有统计学意义(P<0.05)。两组患者HAMD评分、HAMA评分,相较于治疗前均有改善,研究组HAMD评分为(34.63±2.61)、HAMA评分为(35.75±2.48),优于对照组HAMD评分(47.68±3.21)和HAMA评分(46.90±3.31),差异有统计学意义(P<0.05)。结论   腕踝针联合揿针治疗带状疱疹后遗神经痛的临床疗效显著,可有效改善患者生活质量、疼痛程度、焦虑及抑郁程度,提升患者睡眠质量。
       Objective  To investigate the clinical efficacy of wrist and ankle acupuncture combined with thumbtack needle in the treatment of postherpetic herpes zoster pain.Methods  Eighty patients with postherpetic neuralgia admitted to Shanghai Huangpu District Hospital of Integrative Medicine from October 2021 to April 2024 were selected for the study,and were divided into a study group and a control group of 40 cases each according to the random number table method.The control group was treated with oral mecoblamin tables;the study group was treated with wrist and ankle acupuncture combined with thumbtack needle.The efficacy of treatment between the two groups was compared;before and after treatment,the visual analogue score(VAS)and Asens Insomnia Scale(AIS),Dermatological Quality of Life Index(DLQI),Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA)were compared.Results  The treatment efficiency was 92.5% in the study group and 75% in the control group.The difference was statistically significant(P<0.05).VAS scores and AIS scores of patients in both groups improved after treatment,and VAS score(1.00±0.45),AIS score(7.15±0.89)of the study group were better than VAS score(2.15±0.36),AIS score(5.65±0.70)of the control group.The differences were statistically significant(P<0.05).The DLQI scores of both groups improved after treatment,and the score of study group(leisure activity score[1.73±0.45],interpersonal interaction score[1.13±0.34],work-study score[0.94±0.25],self-perceived symptom score[1.83±0.38],daily activities score[0.98±0.28])were higher than those of the control group(leisure activity score[2.06±0.40],interpersonal score[1.81±0.39],work-study score[1.08±0.38],conscious symptom score[2.01±0.34],daily activity score[1.10±0.30]).The differences were statistically significant(P<0.05).HAMD scores and HAMA scores of patients in both groups,showed significant improvement after treatment,and HAMD scores(34.63±2.61)and HAMA scores(35.75±2.48)of the study group were better than HAMD scores(47.68±3.21)and HAMA scores(46.90±3.31)of the control group.The difference was statistically significant(P<0.05).Conclusions  The clinical efficacy of wrist and ankle acupuncture combined with thumbtack needle in the treatment of postherpetic pain is remarkable,effectively improving the quality of life,pain,anxiety and depression,and enhancing the quality of sleep of patients.
论著

安罗替尼联合不同 ALK 抑制剂治疗非小细胞肺癌的疗效比较

Comparion of the therapeutic effect of anlotinib combined with ALK inhibitors in treating non-small cell lung cancer

:171-178
 
       目的 评价不同间变性淋巴瘤激酶(ALK)抑制剂联合安罗替尼治疗非小细胞肺癌(NSCLC)的疗效。方法 收集ALK突变阳性NSCLC患者的临床资料,筛选服用ALK抑制剂疗效不佳再加用安罗替尼的病例。根据不同的用药方案分为阿来替尼+安罗替尼,塞瑞替尼+安罗替尼和克唑替尼+安罗替尼三个组别。记录患者联合用药前最近一次的影像学检查结果,并以此为基线按Recist1.1评价疗效,以病情进展、患者死亡、停药、改变治疗方案为终点计算各组患者的无事件生存期(EFS),收集肿瘤标志物、血常规和肝功、心功能、肾功能生化检测等指标数据,统计分析患者联合用药前后各项指标的变化。结果 经筛选,共纳入49例患者的临床数据。阿来替尼+安罗替尼组有23例,疾病控制率(DCR)为86.96%;平均EFS为(10.8±3.6)个月,中位EFS为8.3个月;塞瑞替尼+安罗替尼组有14例,DCR为71.43%;平均EFS为(6.5±2.9)个月,中位EFS为5.6个月;克唑替尼+安罗替尼组有12列,DCR为66.67%;平均EFS为(7.7±3.2)个月,中位EFS为7.2个月。阿来替尼+安罗替尼组的平均EFS长于另外两组(P<0.05)。各研究组肿瘤标志物仅有CyFra21-1在克唑替尼+安罗替尼组在联合用药后升高(P<0.05),生化检测和血常规指标在用药前后差异无统计学意义(P>0.05)。  ALK抑制剂与安罗替尼联用,疗效最好为阿来替尼,其次为塞瑞替尼,最后为克唑替尼。三种ALK抑制剂与安罗替尼联用后,均未导致心、肝、肾功能和血细胞损害。
      Objective  To evaluate the efficacy of different anaplastic lymphoma kinase(ALK)inhibitors combined with anlotinib in the treatment of non-small cell lung cancer(NSCLC).Methods  Clinical data of drug resistant NSCLC patients with ALK positive mutation was collected who were treated with ALK inhibitors and anlotinib synchronously.According to different regimens,three groups were set,alectinib+anlotinib,ceritinib+anlotinib,and crizotinib+anlotinib.The latest imageological examination  results of the patient before the synchronous therapy was set as the baseline to evaluate the therapeutic effect according to Recist1.1.The event free survival(EFS)of each group was calculated with disease progression,patient death,treatment discontinuation and changing regimen as endpoints.Data of tumor markers,hematology test,liver function,cardiac function,renal function biochemical examination was collected and analyzed statistically before and after the combination therapy,with P<0.05 as the statistically significant difference.Results  After screening,clinical data of 49 patients were collected.Twenty-three patients in the alectinib+anlotinib group,with a disease control rate(DCR) of 86.96%;mean EFS was(10.8±3.6)months,median EFS of 8.3 months;14 patients in the ceritinib+anlotinib group,with a DCR of 71.43%,mean EFS was(6.5±2.9)months,median EFS was 5.6 months;12 patients in the crizotinib+anlotinib group,with a DCR of 66.67%,mean EFS was(7.7±3.2)months,median EFS was 7.2 months.EFS of alectinib+anlotinib group was longer significantly than the other two groups(P<0.05).Only CyFra21-1,increased significantly after the combination of crizotinib and anlotinib(P<0.05).No statistically significant difference in biochemical test and hematology test before and after the treatment(P>0.05).Conclusions  The therapeutic effect of ALK inhibitors with anlotinib was ordered,alectinib being the most effective,followed by ceritinib and finally crizotinib.The combination of ALK inhibitors with anlotinib did not cause any abnormal results in the examination of heart,liver,kidney and blood cells.
论著

心房颤动患者射频消融术中清醒状态下电复律疗效观察

Efficacy of awake electrical cardioversion during radiofrequency ablation of atrial fibrillation

:166-170
 
       目的 探讨术中未恢复窦性心律需要行电复律的心房颤动(房颤)患者在清醒和镇静两种状态下的安全性及有效性。方法 选择2022年1月—2023年12月100例接受射频消融术中行同步直流电复律的持续性房颤患者进行研究,采用随机数字表法将患者分为观察组(清醒状态)和对照组(镇静状态),其中观察组和对照组各为50例。观察两组患者接受电复律的成功率、复发率和不良事件发生率(呼吸抑制、低血压、谵妄、肺水肿、心律失常)等指标。结果 观察组和对照组首次电复律成功分别有48、49例,成功率分别为96%、98%,组间比较差异无统计学意义(P=0.558)。观察组术后30 min内有2例复发,对照组术后30 min内无复发,组间比较差异无统计学意义(P=0.153)。在不良反应方面,观察组共发生1例心律失常事件,1例低血压事件,不良反应的总发生率为4%。对照组共发生3例呼吸抑制事件、2例谵妄事件、1例心律失常事件、2例低血压事件,不良反应的总发生率为16%,组间比较差异有统计学意义(P=0.046)。结论 对持续性房颤患者在射频消融术中,处于清醒状态下行电复律也具有良好的临床疗效,可以减少不良事件的发生,安全性更高。
  Objective  To compare the safety and efficacy of awake state and sedation state in patients with atrial fibrillation(AF)who did not recover sinus rhythm and needed electrical cardioversion during operation.Methods  A total of 100 patients with persistent atrial fibrillation who underwent synchronous direct current cardioversion during radiofrequency ablation from January 2022 to December 2023 were selected and divided into the observation group(awake state)and the control group(sedation state)according to the random number table method,with 50 cases in each group.The success rate of electrical cardioversion,recurrence rate and incidence of adverse events(respiratory depression,hypotension,delirium,pulmonary edema,arrhythmia)were observed.Results  The first electrical cardioversion was successful in 48 and 49 patients in the observation group and the control group,and the success rates were 96% and 98%,respectively.There was no significant difference between the two groupsP=0.558).There were 2 cases of  recurrence in the observation group and no  recurrence in the control group within 30 minutes after operation,and there was no significant difference between the two groups(P=0.153).In terms of adverse reactions,there were 1 case of arrhythmia event and 1 case of hypotension event in the observation group,and the total incidence of adverse reactions was 4%.There were 3 cases of respiratory depression events,2 cases of delirium events,1 case of arrhythmia events,and 2 cases of hypotension events in the control group.The total incidence of adverse reactions was 16%,and the difference between the two groups was statistically significant(P=0.046).Conclusions  Electrical cardioversion in awake state during  radiofrequency ablation of persistent atrial fibrillation has a good clinical efficacy and safety,which can reduce the occurrence of adverse events.
出版者信息








《广州医药》公众号